Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Gastroesophageal reflux disease (GERD)
* Erosive esophagitis
* Healing of duodenal ulcers
* *Helicobacter pylori* eradication (in combination regimens)
* Zollinger-Ellison syndrome
## Adult Dosing
* **GERD/Erosive Esophagitis:** 20 mg or 40 mg orally once daily. Treatment duration for erosive esophagitis is typically 4-8 weeks. For GERD without esophagitis, 4 weeks of treatment is often sufficient.
* **Duodenal Ulcer Healing:** 40 mg orally once daily. Healing typically occurs within 4 weeks.
* ***H. pylori* Eradication:** 40 mg orally twice daily for 7-14 days, in combination with antibiotics (e.g., amoxicillin and clarithromycin or metronidazole and clarithromycin).
* **Zollinger-Ellison Syndrome:** 40 mg orally once or twice daily. Doses may be titrated higher based on acid output; maximum recommended dose is 80 mg every 8 hours.
## Pediatric Dosing
* **GERD/Erosive Esophagitis:**
* **1 year to < 5 years:** 10 mg orally once daily for up to 8 weeks.
* **5 years to < 12 years:** 20 mg orally once daily for up to 8 weeks.
* **≥ 12 years:** 40 mg orally once daily for up to 8 weeks.
* *Note:* Dosing for *H. pylori* eradication and Zollinger-Ellison syndrome in pediatric patients is not well established and requires specialist consultation.
## Dose Adjustments
No dose adjustment is generally required for hepatic or renal impairment, although caution may be advised in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine) with prolonged use, hypomagnesemia, vitamin B12 deficiency, systemic lupus erythematosus (new or exacerbation).
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, iron salts, mycophenolate mofetil. Concurrent use may decrease absorption.
* **Methotrexate:** Pantoprazole may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole may inhibit CYP2C19, potentially increasing levels of drugs like clopidogrel (though clinical significance is debated) and voriconazole.
## Monitoring
* Monitor for signs and symptoms of *C. difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels, especially in patients on long-term therapy or those taking concomitant diuretics or digoxin.
* Monitor for signs and symptoms of bone fractures.
* Assess for vitamin B12 deficiency with prolonged use.
## Clinical Pearls
* Pantoprazole is often administered 30-60 minutes before a meal.
* Oral formulations should not be crushed or chewed.
* For IV administration, reconstitution and dilution are required; consult specific institutional guidelines.
* Long-term PPI use is associated with increased risk of certain adverse events. Re-evaluate the need for therapy periodically.
***
**Disclaimer:** This information is intended for clinical decision support and does not replace comprehensive drug references or local institutional protocols. Always verify current prescribing information and patient-specific factors before initiating or modifying therapy.
